Related Experiment Video
Updated: Jul 17, 2026
05:10
Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice
Published on: October 3, 2010
[Risk stratification in medulloblastoma: screening for molecular markers]
M Ebinger1, L Senf, W Scheurlen
1Abteilung für Molekulare Pathologie, Institut für Pathologie, Universitätsklinikum Tübingen.
Klinische Padiatrie
|May 12, 2006
Summary
This study investigated molecular markers for medulloblastoma treatment stratification. C-MYC amplification and tumor suppressor gene methylation showed no clear association with patient outcomes, suggesting complex therapeutic strategies are needed.
Area of Science:
- Molecular Oncology
- Pediatric Neuro-oncology
- Cancer Genomics
Context:
- Medulloblastoma is a common pediatric brain tumor requiring effective therapy stratification.
- Identifying reliable molecular markers is crucial for predicting treatment response and patient outcomes.
- Current therapeutic strategies need refinement based on molecular profiling.
Purpose:
- To evaluate C-MYC amplification as a predictive marker for medulloblastoma.
- To assess the promoter methylation status of key tumor suppressor genes (CASP8, TIMP3, CDH1, CDKN2A, MGMT) in medulloblastoma.
- To investigate the expression of GAS7 as a potential molecular marker in medulloblastoma.
Summary:
- Analysis of 69 medulloblastoma samples revealed no significant association between C-MYC amplification and clinical outcome.
- Promoter methylation was non-randomly distributed, with high methylation observed for CASP8; however, no correlation with clinical outcome was found.
- GAS7 expression was detected in 20/29 tumors, but its role as a tumor suppressor is considered improbable.
Impact:
- Findings suggest C-MYC amplification is not a reliable prognostic marker for medulloblastoma in this cohort.
- The methylation status of tumor suppressor genes, particularly CASP8, may offer potential therapeutic targets (e.g., via interferon gamma).
- GAS7 is unlikely to have an antitumorigenic role in medulloblastoma, despite its expression in tumor samples.
